Incyte Corporation (NASDAQ:INCY) traded with a cut of -1.62 points or -2.06% at $76.87 per share. As per the last available information, the stock aggregated $16.79 million in upticks and $15.03 million in downticks, keeping the net money flow capped at $1.76 million. The up/down ratio was found to be 1.12. For the week, the shares have seen a change of -0.31% in the share price.A block trade of $2.51 million in upticks and $0 million in downticks also took place during the day. The up/down ratio for the block stood at 0. The net money flow for this transaction was $2.51 million.
The stock has recorded a 20-day Moving Average of 5.44% and the 50-Day Moving Average is 0.17%. The company shares have dropped 28.2% in the past 52 Weeks. On September 16, 2015 The shares registered one year high of $133.62 and one year low was seen on February 11, 2016 at $55. The 50-day moving average is $78.33 and the 200 day moving average is recorded at $80.83. S&P 500 has rallied 1.93% during the last 52-weeks.
Incyte Corporation (NASDAQ:INCY): The stock opened at $78.84 on Tuesday but the bulls could not build on the opening and the stock topped out at $79.40 for the day. The stock traded down to $76.04 during the day, due to lack of any buying support eventually closed down at $77.60 with a loss of -1.13% for the day. The stock had closed at $78.49 on the previous day. The total traded volume was 1,301,253 shares.
Currently the company Insiders own 13.7% of Incyte Corporation shares according to the proxy statements. Institutional Investors own 95.83% of Incyte Corporation shares. On the companys insider trading activities, Swain Paula J, officer (EVP, Human Resources) of Incyte Corp, unloaded 13,531 shares at an average price of $76.96 on January 15, 2016. The total amount of the transaction was worth $1,041,346, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f